Curious to see the emissions of the organizations you buy from or invest in?
Book a demo for a pilot project
Book a demo for a pilot project
The Novo Nordisk Foundation, headquartered in Denmark (DK), is a prominent entity in the Other Business Services sector, specifically focusing on healthcare and life sciences. Established in 1923, the foundation has played a pivotal role in advancing medical research and innovation, particularly in diabetes care and hormone replacement therapies.
With a commitment to improving global health, the foundation supports various initiatives, including funding research projects and educational programmes. Its unique approach combines philanthropy with a strong emphasis on scientific advancement, positioning it as a leader in the industry. Notable achievements include significant contributions to diabetes research and the establishment of the Novo Nordisk Research Centre, which underscores its dedication to fostering innovation in healthcare.
+4 vs industry average
Novo Nordisk Foundation’s score of 40 is higher than 56% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Business Services is among the least carbon-intensive industries
The Business Services industry has reduced its overall emissions by 25% since 2018
Scope 3 accounts for ••• of total emissions.
Novo Nordisk Foundation, based in DK, reported total carbon emissions of approximately 614 million kg CO2e in 2026. This total includes around 34 million kg CO2e from Scope 1 emissions, 16 million kg CO2e from Scope 2 emissions, and 564 million kg CO2e from Scope 3 emissions. In the previous year, 2025, their total emissions were about 667 million kg CO2e, comprising approximately 33 million kg CO2e from Scope 1, 17 million kg CO2e from Scope 2, and 617 million kg CO2e from Scope 3.
While the foundation reports its own emissions, its climate commitments are linked to related organisations. Novo Nordisk A/S, for instance, has pledged to achieve zero emissions from its operations and transportation by 2030 for Scope 1 and Scope 2. Novo Nordisk A/S also aims for net-zero emissions by 2045 across all scopes. Additionally, Novozymes commits to reaching net-zero greenhouse gas emissions across its value chain by 2050, from a 2018 base year.
2025
Near-zero scope 1 & 2
Target to achieve near-zero emissions for direct operations and purchased energy
2030
62% reduction in total GHG
Vs 2019 baseline. Validated by SBTi. Includes full supply chain.
2040
50% reduction in Scope 3 intensity
Across purchased goods and services and logistics.
Showing SBTi-validated targets only. Sign up or sign in to see all disclosed climate targets.
No scope 3 category breakdown has been disclosed yet.


PCAF scored Scope 1, 2 and 3 for 2M+ organizations, including private ones.
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more